发明名称 |
USE OF A TETRASUBSTITUTED PYRAZOLO[4, 3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY |
摘要 |
The present invention relates to methods of delaying progression to end stage renal disease (ESRD) in patients comprising administration of 1-(2-ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methylpyridin-2-yl)amino)-N-(methylsulfonyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide. The present invention also includes administration of pharmaceutical compositions for delaying progression to ESRD.;1-(2-ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methylpyridin-2-yl)amino)-N-(methylsulfonyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide |
申请公布号 |
US2016136170(A1) |
申请公布日期 |
2016.05.19 |
申请号 |
US201615002530 |
申请日期 |
2016.01.21 |
申请人 |
Pfizer Inc. |
发明人 |
Clerin Valerie;Gale Jeremy;Tamimi Nihad |
分类号 |
A61K31/519;A61K45/06 |
主分类号 |
A61K31/519 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating macroalbuminuria in a patient comprising the step of administering to the patient, in need of such treatment, a therapeutically effective amount of a combination of (i) 1-(2-Ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methylpyridin-2-yl)amino)-N-(methylsulfonyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof, and (ii) an angiotensin converting enzyme inhibitor. |
地址 |
New York NY US |